Since 50% of colorectal cancer patients content k-ras mutation which leads to resistant disease to epithelial growth factor receptor antibody. We use anti-interleukin-6 receptor antibody as a therapeutic method and the inhibition of tumor growth and the invasiveness have been found in both cell and animal tumor models. This antibody could be the targeted drugs that overcome k-ras mutated cancer.

Targeted drug Erbitux is not effective against k-ras mutated colorectal cancer. The patented technology is characterized using anti-interleukin-6 antibody as a substitute for Erbitux, as a targeted drug for k-ras mutated colorectal cancer. This is the first method to suppress the growth and invasiveness of k-ras mutated colorectal cancer.

The anti-interleukin-6 receptor antibody Tocilizumab (Artemra), using in anti-rheumatoid arthritis has been found possessing anti-k-ras mutated colorectal cancer ability. It has been confirmed to use 1mg/kg every two days can inhibit the tumor growth and invasion in an animal model. Half of 15,000 new patients with colorectal cancer in Taiwan per year are k-ras mutated, leading to the estimated annual output value that may exceed 2 billion yuan.